摘要
目的分析Ki-67在不同分子亚型的乳腺浸润性导管癌中的表达，初步探讨其意义。方法采用免疫组织化学法测定126例乳腺浸润性导管癌标本的雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER-2）、Ki-67的表达以明确其分子亚型，同时分析Ki-67的表达与各分子亚型及临床病理特征的关系。结果Ki-67的表达在患者年龄的分布、肿物的大小中差异均无统计学意义（均P〉0．05），而在组织学分级、淋巴结转移中的差异均有统计学意义（均P〈0．05），其表达与ER、PR表达呈负相关（r=-0．273，P=0．002；r=-0．242，P=0．007），与HER-2表达呈正相关（r=0．245，P=0．006）。Ki-67在LumianlA中均呈低表达（17／17），在其他分型中均呈高表达，其中，〉50％的高表达率在各型所占比例随分型程度递增，且不同分子亚型间Ki-67的表达差异有统计学意义（，=62．392，P〈0．05）。结论Ki-67表达高低与乳腺浸润性导管癌组织学分级、淋巴结转移及分子分型有关，其高表达往往提示预后不良，因此有必要与ER、PR、HER-2联合作为临床病理的常规检测项目。
Objective To analyze Ki-67 expression and explore its significance in different molecular subtypes of breast invasive ductal carcinoma （ IDC ） . Methods The expressions of estrogen receptor （ER）, progesterone receptor （PR）, human epidermal growth factor receptor-2 （HER-2） and Ki- 67 were detected in 126 cases of IDC by immunohistochemical staining. Then the molecular subtype of each case of 1DC was determined. Statistical analysis was performed to determine the relationship between Ki-67 expression and the molecular subtypes with clinicopathological features of IDC. Results There was no statistically significant difference of Ki-67 expression in age and tumor size （ P 〉 0. 05 ）. However, significant difference existed in histological grading and lymph node metastasis （ P 〈 0. 05 ）. The expression level of Ki- 67 was negatively correlated with ER expression（r = -0. 273, P =0. 002） and PR expression（r = -0. 242, P = 0. 007 ） and positively with HER-2 expression （ r -- 0. 245, P = 0. 006 ）. A low expression of Ki-67 was in LumianlA subtype （ 17/17 ） and high expression in other molecular subtypes. Moreover, the rate of high expression （ Ki-67 LI 〉 50% ） in each subtype progressively increased with the degree of molecular typing and Ki-67 expression in different molecular subtypes showed significant difference （ P 〈 0. 05 ）. Conclusions The expression level of Ki-67 is correlated with histological grading and molecular type of IDC. High expression of Ki-67 carries poor prognosis. Thus it is necessary to perform a variety of routine clinicopathological examinations, such as Ki-67, ER, PR and HER-2.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第36期2895-2897,共3页
National Medical Journal of China
